

CURRICULUM VITAE ET STUDIORUM
OF
IRENE CACCIOLA

PERSONAL DETAILS

- Nationality: Italian
- Date of birth: March 21, 1971
- Place of birth: Messina, Italy
- Address: Via circuito 55 Torre Faro 178, 98122 Messina Italy
- E-Mail: icacciola@unime.it
- Telephone numbers +39 339 3595451 (mobile), +39 090 2212358 (office)

CURRENT POSITION-ACADEMIC CARRIER

- From December 2021 to date:
Associate Professor, MD Medicine and Hepatology Unit, Department of Clinical and Experimental Medicine University Hospital of Messina
- March 2008 – November 2021
Assistant Professor, MD Clinical and Biomolecular Hepatology Unit, Department of Internal Medicine, University Hospital of Messina.

EDUCATION

- May 2006 to February 2008 and July 2001 to June 2005: Research Fellow at Department of Internal Medicine, University of Messina, for the project “Occult HBV Infection in the pathogenesis of Chronic Liver Diseases and Epatocellular Cacinoma”.
- October 2000: Board in Internal Medicine (cum Laude), University of Messina, Italy.
- July 1996: Medical Doctor in Medicine and Surgery (cum Laude), University of Messina, Italy.

PROFESSIONAL AWARDS

- February 2023: Award of the national scientific qualification as Full Professor SCSSC 06 B1 (Internal Medicine).
- November 2020: Award of the national scientific qualification as Associate Professor SCSSC 06 B1 (Internal Medicine).
- March 2017: Award of the national scientific qualification as Associate Professor SCSSC 06 D4 (Cutaneous Disease, Infectious Disease and Gastrointestinal Disease)

ACADEMIC ROLES

- From October 2022 to date, Course Leader and developer of the Graduate Course in Medicine and Surgery with Biotechnological pathway of the University of Messina
- From July 2019 to date Member of the "ERASMUS" commission of the University of Messina
- From May 2019 to date: Referral for Quality, Research and the Third Mission for the Department of Clinical and Experimental Medicine
- From October 2019 to October 2022 Deputy Course leader of the Degree Course of Medicine and Surgery of the University of Messina

TEACHING ACTIVITY

- From October 2022 to date Component of the Board of Professors for Phd (DOT0814152, cicle XXIV) in “Translational Molecular Medicine and Surgery” University of Messina.
- From July 2017 to date: Coordinator for International Mobility of the Course Degree in Medicine and Surgery
- From October 2016 to date: Member of the Technical Commission for Teaching Pedagogical Programming of the Course Degree in Medicine and Surgery of the University of Messina.
- From October 2009 to date: Member of teaching team of the Integrated Course of Semeiotic and Clinical Methodology and of the Integrated Course of Internal Medicine for the degree in Medicine and Surgery at University of Messina
- From October 2011 to date: Member of teaching team of the Internal Medicine for the Specializations in Internal Medicine, Geriatrics, General Medicine, at University of Messina.
- From 2008 to 2010 (Cycles XXIV, XXV e XXVI): Board of Professor for Phd in "Clinical and Bio-molecular Hepato-gastroenterology in adolescents and adults”.

CLINICAL EXPERIENCE

- From September 2019 to date Deputy Director of Medicine and Hepatology Unit. University Hospital of Messina

- From April 2013 to date: Referring physician with the authority to prescribe and validate specific antiviral drugs for the treatment of chronic hepatitis and cirrhosis Hepatitis C Virus related, by decree of the Department of Health of the Region of Sicily.
- From March 2008 to date: M.D. at Department of Internal Medicine University Hospital of Messina, Clinical and Biomolecular Hepatology Unit.

PARTICIPATION IN RESEARCH PROJECTS FINANCED BY PUBLIC AND PRIVATE ENTITIES

- a) **rAIdD title** – Rete eHealth : AI e strumenti ICT innovativi orientati alla Diagnostica Digitale – Codice locale Progetto T2-AN-04 CUP J43C22000380001” – DGRIC-MDS-P prot. n. 3056 02 agosto 2022
- b) **PRIN 2022**, title “Deciphering the key virological determinants underlying the replicative and pathogenetic activity of Hepatitis D Virus (HDV) in treated and untreated Hepatitis B Virus and HDV coinfecting patients
- c) **SAMOTHRACE** (Sicilian Micro nanoTech Research And Innovation Center) title -WP3 Health Advanced Micro-Nano Technologies and Devices for Health, task 3.2 e 3.4 “Advanced BioChip Design, Development and Characterization”- UniME – FBK. Da ottobre 2022 in Corso.
- d) **Fellowship program 2018 (Gilead)**: Title project : “Prevalenza dell'infezione da virus dell'epatite C in pazienti consecutivamente ricoverati in reparti di Medicina Interna e di Chirurgia Generale e d'Urgenza del Policlinico Universitario di Messina”
- e) **P.O.N. Hippocrates 2007-2013** (Identification code: PON02_00355_2964193) Title project Identificazione dei nuovi bio-marcatori diagnostici/prognostici per l'infezione cronica “manifesta ed occulta” da virus della epatite B (HBV) e nella coinfezione tra HBV e Virus “Delta”. (Principal investigator Prof. G. Raimondo)
- f) **PRIN 2010-2012** Title: Analisi molecolare di HBV isolati da soggetti vaccinati contro l'epatite B 15-18 anni fa e che hanno sviluppato infezione da HBV. Coordinatore scientifico prof. Alessandro R. Zanetti, Responsabile scientifico Prof. T. Pollicino. Area 06 Ateneo/Ente: Università degli Studi di MESSINA. Protocollo: 20088HNWSP_003
- g) **Project Financed by Italian Association of Cancer Research AIRC 2005-7**
Title: Study of virus/cell interplay in occult hepatitis B virus infection associated with hepatocellular carcinoma Principal investigator Prof G. Raimondo
- h) **Project Financed by Italian Association of Cancer Research AIRC 2003-4**
Title: Tumorigenic properties of hepatitis B virus (HBV) isolated from patients with occult HBV infection. Principal investigator Prof G. Raimondo

▪ ***Expertise as co-investigator and study coordinator in 24 clinical trials.***

1. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults With Compensated Cirrhosis From Non Alcoholic Steatohepatitis (NASH) **IM025-017**
2. A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to evaluate the Safety and Efficacy of lenvatinib, (E7980/MK-7902) With Pembrolizumab (MK-3475) in combination with trans-arterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic Hepatocellular Carcinoma (LEAP-012) **MK7902-012**
3. Randomized, Double-blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog (NA) Regimen Compared to NA Alone in e Antigen-negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection. **The REEF-2 Study.**
4. A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection. **The REEF-1 Study**
5. A Phase 3, matrix design, partially double-blind, randomized study of the efficacy and safety of 50 mg Lonafarnib/ 100 mg Ritonavir bid with and without 180 mcg peg ifn-alfa-2a for 48 weeks compared with peg ifn-alfa-2a monotherapy and placebo treatment in patients chronically infected with hepatitis delta virus being maintained on anti-hbv nucleos(t)ide therapy (D-LIVR). **EIG-LNF-011**
6. Clinical protocol A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation. Clinical protocol **CA209-9DX.**
7. Study 2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma Clinical protocol MGL-3196-11 A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation. Clinical protocol. **MGL-3196-11**

8. "A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation" **BMS CA209-9DX**
9. "A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation" **BMS CA209-9DX**
10. "Evidenze nel Mondo Reale (Real World Evidence) relative all'Efficacia (Effectiveness) ed all'Utilizzo nella Pratica Clinica di Glecaprevir/Pibrentasvir in Pazienti Affetti da Infezione Cronica da Epatite C di Genotipo 1-6" - Studio **ABBVIE P16-919 STUDIO MARS**
11. "A Phase 3b study to evaluate the long-term outcomes following treatment with Abbvie DAAs (subjects will be dosed on-study) with or without Ribavirin (RBV) in adults with genotype 1 Chronic Hepatitis C Virus (HCV) Infection" **ABBVIE M14-423. TOPAZ I**
12. "A randomized, Open Label, Multicentre Study, to Evaluate the Safety and Antiviral Activity, of the combination of ABT450/ritonavir/ABT267 and ABT 333 with and without Ribavirin in Treatment experienced Subject with Genotype 1b Chronic Hepatitis C virus (HCV) infection." AbbVie **M13-389 PEARL II**
13. "A randomized, open label, phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection". Janssen-Cilag **VX950-C211**
14. "Multicentre, Open Label, Early Access Program of Telaprevir in Combination with peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C subjects with severe Fibrosis and Compensated Cirrhosis". Janssen-Cilag **VX-950HEP3002**
15. "Phase III, randomized , double -blind trial to evaluate the efficacy, safety and tolerability of TMC 435 vs. Telaprevir, both in combination with PegIFna2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null or partial responders to prior PegIFNa and ribavirin therapy". Janssen-Cilag **TMC435 HPC3001A**
16. "A Phase 3 study with Asunaprevir and Daclatasvir(DUAL) for Null or Partial responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment Naive Subjects with Chronic Hepatitis C Genotype 1b Infection". Janssen-Cilag **BMS AI447-028**
17. "An open label re-treatment study with peg Interferon Alfa 2a and BMS 790052 with or without BMS 650032 for subject with chronic hepatitis C". **BMS AI444026**

18. “A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatitis C”. BMS **AI444-046**
19. “Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis C Genotype 1b who are Treatment Naive or Prior Relapsers to Alfa/RBV Therapy .” BMS **AI 452 021A**
20. “The use of human Albumin for the treatment of Ascites in patients with hepatic cirrhosis: a multicentric, open- label randomized clinical trial” **FARM6P824B**
21. A study of Lamivudine in patients with anti-HBe positive chronic hepatitis B Infection” (GLaxoWellecome **NUC B 3014**);
22. “Study of extended lamivudine treatment for hepatitis B patients previously enrolled in phase II or phase III lamivudine trials (GLaxoWellecome **NUC B 3017**);
23. “Double Blind Randomized multicentre study of Lamivudine added to the current treatment in the therapy of chronic hepatitis B in HBV-DNA/anti HBe positive patients” (Glaxo Wellecome Lamivudine Study **ZEF 01**)
24. “Seocalcitol versus placebo in advanced hepatocellular carcinoma” (**Phoenix International EBC 9801 INT**).

SCIENTIFIC MEMBERSHIPS

- Member of the Società Italiana di Medicina Interna (SIMI)
- Member of Associazione Italiana Studio Fegato (AISF)
- From 2016-2019 Member of advisory board “Gruppo Epatologico Calabro-Siculo (Neo-GRECAS)”

EDITORIAL BOARD MEMBER FOR INTERNATIONAL JOURNALS

- Frontiers in Oncology, in Gastrointestinal Cancer (Associate Editor)
- Annals of Hepatology (Associate Editor)
- Journal of Personalized Medicine -MDPI (Board Member)
- American Journal of Internal Medicine (Board Member)

REVIEWER ACTIVITY MEMBER FOR INTERNATIONAL JOURNALS

- Gastroenterology
- Journal of Clinical Medicine
- Journal of Hepatology
- Alimentary Pharmacology & Therapeutics
- Digestive e liver Disease
- Annals of Infectious Disease and Epidemiology
- BMC Gastroenterology
- BMJ Open
- MDPI
- Hepatic Medicine: Evidence and Research
- Hepatology International
- Journal of Geriatrics & Palliative Care
- Journal of Clinical Virology
- World Journal of Gastroenterology

RESEARCH ACTIVITIES

The research activity was essentially oriented towards liver diseases, with particular regard to those related

to hepatitis virus infection, metabolic dysfunction-associated fatty liver disease, liver cirrhosis and its complications including hepatocellular carcinoma. The published works were the products of "translational" or more purely clinical studies. The results of the studies have been published in high-profile journals including the New England Journal of Medicine, Lancet, Journal of Hepatology, Hepatology, American Journal of Gastroenterology etc.

Numero Totale Pubblicazioni: 61

Impact Factor (IF) Totale 781,4 IF medio 12,8

Numero Totale Citazioni 3822

***h*-index (web of science) 24**

Web of Science Researcher ID: K-1174-2019

Website <https://www.unime.it/it/persona/irene-cacciola/curriculum>

Publications

1. Asero C, Giandalia A, **Cacciola I**, Morace C, Lorello G, Caspanello AR, Alibrandi A, Squadrito G, Russo GT High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease. *J Clin Med*. 2023 Apr 13;12(8):2858. doi: 10.3390/jcm12082858.PMID: 37109195 **IF4.96**
2. Leonardis F, Gitto L, Favi E, Oliva A, Angelico R, Mitterhofer A, **Cacciola I**, Santoro D, Manzia TM, Tisone G, Cacciola R. A Keynesian perspective on the health economics of kidney transplantation would strengthen the value of the whole organ donation and transplantation service. *Front Public Health*. 2023 Mar 27;11:1120210. doi: 10.3389/fpubh.2023.1120210. eCollection 2023.PMID: 37050945 **IF 6,46**
3. Licata A, Russo GT, Giandalia A, Cammilleri M, Asero C, **Cacciola I** Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes. *J Pers Med*. 2023 Mar 20;13(3):558. doi: 10.3390/jpm13030558. Review. **IF3,52**
4. Brancaccio G, Coco B, Nardi A, Quaranta MG, Tosti ME, Ferrigno L, **Cacciola I**, Messina V, Chessa L, Morisco F, Milella M, Barbaro F, Ciancio A, Russo FP, Coppola N, Blanc P, Claar E, Verucchi G, Puoti M, Zignego AL, Chemello L, Madonia S, Fagioli S, Marzano A, Ferrari C, Lampertico P, Di Marco V, Craxì A, Santantonio TA, Raimondo G, Brunetto MR, Gaeta GB, Kondili LA; PITER collaborating investigators. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination. *Int J Infect Dis*. 2023 Apr;129:266-273. doi: 10.1016/j.ijid.2023.02.006. **IF 12,7**
5. Maria Stella Franzè, Roberto Filomia, Gaia Caccamo, Concetta Pitrone, Angela Alibrandi, Carlo Saitta, Amalia Rita Caspanello, Clelia Asero, Vittoria Arcadi, Giovanni Raimondo and **Irene Cacciola** Hypergammaglobulinemia before Starting DAA Therapy Is A Strong Predictor of Disease Progression in Cirrhotic Patients Even after HCV Clearance. *J. Pers. Med*. 2022, 12(11), 1794; <https://doi.org/10.3390/jpm12111794> in press **IF3,52**
6. **Cacciola I**. Effects of PPIs in cirrhotic patients: What do we really know? *Gastroenterology*. 2022 Jul; 163(1):47-49. doi: 10.1053/j.gastro.2022.04.039doi: **IF 22.7**
7. Vincenza Calvaruso, Ciro Celsa, Roberta D'Ambrosio, Fabio Simone, Salvatore Petta, **Irene Cacciola**, Marco Enea, Salvatore Battaglia, Massimo Licata, Elisabetta Degasperì, Giuseppe Cabibbo, Lorenza Di Marco, Grazia Pennisi, Marta Borghi, Vincenzo Di Martino, Roberto Filomia, Yasmin Abdel-Hadi, Luciano Crapanzano, Giovanni Raimondo, Pietro Lampertico, Antonio Craxì, Calogero Cammà, Vito Di Marco. RESIST-HCV criteria to monitor progression of low-risk esophageal varices in patients with compensated cirrhosis after HCV eradication.

The SIMPLE study. American Journal of Gastroenterology 2022 Jun 17. doi: 10.14309/ajg.

IF 10,9

8. Gianluca Bagnato, Egidio Imbalzano, Caterina Oriana Aragona, Carmelo Ioppolo, Pierpaolo Di Micco, Daniela La Rosa, Francesco Costa, Antonio Micari, Simona Tomeo, Natalia Zirilli, Angela Sciacqua, Tommaso D'Angelo, **Irene Cacciola**, Alessandra Bitto, Natasha Irrera, Vincenzo Russo, William Neal Roberts, Sebastiano Gangemi, Antonio Giovanni Versace. New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress. *Medicina (Kaunas)*. 2022 Apr 11;58(4):530. doi: 10.3390/medicina58040530. **IF 2.43**
9. Saitta C, Caruso A, Maimone S, Filomia R, **Cacciola I**, Caccamo G, Franzè MS, Pitrone C, Alibrandi A, Gaeta M, Mandraffino G, Squadrito G, Raimondo G. Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity. *Intern Emerg Med*. 2022 Mar 24. doi: 10.1007/s11739-022-02971-5. **IF 5.4**
10. **Cacciola I**, Pitrone C, Franzè MS, Mazzeo M, Muscianisi M, Porcari S, Pintabona G, Morace M, Basile G, Cucinotta E, Pollicino P, Raimondo G. Prevalence of hepatitis B and C viral infections in hospitalized patients with increased liver enzyme levels and with no known history of hepatic disease. *Annals of Hepatology Ann Hepatol*. 2021 Nov 6:100578. doi: 10.1016/j.aohep.2021.100578 **IF 3,4**
11. Caccamo G, Franzè MS, Saffioti F, Pitrone C, Porcari S, Alibrandi A, Filomia R, Mondello P, **Cacciola I**, Saitta C, Squadrito G, Raimondo G, Maimone S. Cirrhotic Patients with Bacterial Infection and Negative Cultures Have a More Advanced Disease and an Increased Short-Term Mortality Rate. *Dig Dis Sci*. 2021 May 26. doi: 10.1007/s10620-021-07047-6. **IF 3,2**
12. Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi Minami RT, Sangiovanni A, Toyoda XF, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LLC, POL S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Francesco Paolo Russo FP, Rob Bielen, Franco Trevisani, Calogero Cammà, Jordi Bruix, Giuseppe Cabibbo, Maria Reig and COLLABORATORS Erica Villa, Esperanza Merino, Eugenio Caturelli, F. Ponziani, Fabio Cartabellotta, Fabio Farinati, Fabio Marra, Fabio Piscaglia, Fabrice Carrat, Federica Buonfiglioli, Federica Cerini, Filip Janssens, Leuven, Filippo Oliveri, Filomena

Morisco, Francesco Bellanti, Francesco Benanti, Francesco Giuseppe Foschi, Francesco Azzaroli, Francisco, Francisco Jorquera, Francisco Rodríguez-Arrondo, Francisco Téllez, Francois D'Heygere, Frederik Nevens, Fukiko Kawai-Kitahata, G. D'offizi, G. Galati, Gabriella Verucchi, Gabriele Missale, Gaetano Bertino, Gaetano Scifo, Gaia Pellegatta, Gamal Esmat, Gasser El-Azab, Geert Robaey, Gerardo Nardone, Giacomo Germani, Gian Ludovico Rapaccini, Gianluca Svegliati-Baroni, Gianluigi Vendemiale, Gianpolo Vidili, Giovanna Lunghi, Giovanni Mazzola, Giovanni Raimondo, Giovanni Squadrito, Giuseppe Mazzella, Guglielmo Borgia, Hans Van Vlierberghe, Hayato Nakagawa, Helene Fontaine, Hideki Sakai, Iliaria Serio, Inmaculada Fernandez, **Irene Cacciola**, Isabelle Vögeli, Javier Ampuero, Javier García-Samaniego, Jean-Pierre Mulkay, Jochen Decaestecker, Johannes Vermehren, Jordi Llaneras, Joseba, Juan A. Pineda, Juan Arenas, Juan Macías, Juan Manuel Pascasio. Hepatocellular carcinoma recurrence after direct acting antiviral therapy: an individual patient data meta-analysis. *Gut*. 2021 Mar 19:gutjnl-2020-323663. doi: 10.1136/gutjnl-2020-323663.

IF 19,8

13. Calvaruso V, Petta S, **Cacciola I**, Cabibbo G, Cartabellotta F, Distefano M, Scifo G, Di Rosolini MA, Russello M, Prestileo T, Madonia S, Malizia G, Montineri A, Digiacomo A, Licata A, Benanti F, Bertino G, Enea M, Battaglia S, Squadrito G, Raimondo G, Cammà C, Craxì A, Di Marco V. Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort. *J Viral Hepat*. 2021 Apr 25. doi: 10.1111/jvh.13523. 19,8

IF 3,7

14. **Cacciola I**, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, Alibrandi A, Franzè MS, Porcari S, Maimone S, Saitta C, Squadrito G, Raimondo G. Over time evaluation of glycaemic control in direct-acting-antiviral treated HCV/diabetic individuals with chronic hepatitis or with cirrhosis. *Liver Int*. 2021 Apr 24. doi: 10.1111/liv.14905.

IF 8,75

15. Franzè MS, Bottari A, Caloggero S, Pitrone A, Barbera A, Lembo T, Caccamo G, **Cacciola I**, Maimone S, Alibrandi A, Pitrone C, Squadrito G, Raimondo G, Saitta C. Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound-detected liver nodules. *Intern Emerg Med*. 2020 Oct 27. doi: 10.1007/s11739-020-02541-7.

IF 5,4

16. Caraceni P, Tufoni M, Zaccherini G, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Simone L, Svegliati-Baroni G, Faggioli S, Laffi G, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Gasbarrini A, De Marco R, Piano S, Nardelli S, Elia C, Roncadori A, Baldassarre M, Bernardi M; ANSWER Study Investigators Marco Domenicali, Ferdinando A Giannone, Agnese Antognoli, Manuela Merli, Chiara Pasquale,

Stefania Gioia, Silvano Fasolato, Antonietta Sticca, Daniela Campion, Alessandro Risso, Giorgio M Saracco, Loredana Prestianni, Federica Fidone, Daniela Maiorca, Agostino Rizzotto; Federica Mirici Cappa, Arianna Lanzi, Elga Neri, Anna Visani Giovanni Perricone, Alberto Alberti, Lucia Cesarini, Chiara Mazzarelli, Marcello Vangeli, Raffaella Viganò, Marco Marzioni, Francesca Capretti, Alba Kostandini, Giulia Magini, Maria Colpani, Tommaso Gabbani, Maria Marsico, Marianna Zappimbulso, Josè Petruzzi, Vincenza Calvaruso, Giovanni Parrella, Nicola Caporaso, Francesco Auriemma, Maria Fabio Pugliese, Annalisa Tortora, Pietro Leo, Mario Angelico, Francesco De Leonardis, Alessandra Pecchioli, Piera Rossi, Giovanni Raimondo, **Irene Cacciola**, Gianfranco Elia, Elisa Negri, Marcello Dallio, Carmelina Loguercio, Alessandro Federico, Dario Conte, Sara Massironi, Giorgio Ballardini Natascia Celli, Maria Rendina, Roberto Bringiotti, Nicola Maurizio Castellaneta, Francesco Salerno, Sergio Boccia Riccardo Guarisco, Alessandra Galioto, Marta Cavallin, Alida Andrealli. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. *J Hepatol.* 2020 Aug 24;S0168-8278(20)33551-0. doi: 10.1016/j.jhep.2020.08.021.

IF 25,1

17. **Cacciola I**, Borgia F, Filomia R, Pitrone C, Franzè M S, Alibrandi A, Squadrito G, Guarneri C, Papaiani V, Cannavò SP, Raimondo G. Outcome of cutaneous psoriasis in hepatitis C virus-infected patients treated with Direct-Acting Antiviral therapy *J Viral Hepat.* 2020 Mar;27(3):333-337.

IF 3,7

18. Calvaruso V, **Cacciola I**, Licata A, Madonia S, Benigno R, Petta S, Bronte F, Conte E, Malizia G, Bertino G, Distefano M, Montineri A, Digiacomo A, Alaimo G, Cacopardo B, Davì A, Guarneri L, Scalisi I, Colletti P, Cartabellotta F, Portelli V, Prestileo T, Averna A, Iacobello C, Mondello L, Scifo G, Russello M, Squadrito G, Raimondo G, Cammà C, Craxì A, DiMarco V; RESIST-HCV (Rete Sicilia Selezione Terapia-HCV). Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. *Am J Gastroenterol.* 2019 May 24.

IF 10,9

19. Cabibbo G, Celsa C, Calvaruso V, Petta S, **Cacciola I**, Cannavò MR, Madonia S, Rossi M, Magro B, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalisi I, Mazzola G, Di Rosolini MA, Alaimo G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrito G, Raimondo G, Trevisani F, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.)

Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. *J Hepatol.* 2019 Apr 6

IF 25,1

20. Musolino C, **Cacciola I**, Tripodi G, Lombardo D, Raffa G, Alibrandi A, Squadrito G, Raimondo G, Pollicino T. Behaviour of occult hepatitis B virus infection in hepatitis C virus infected patients under treatment with direct-acting antivirals. *Antiviral Ther.* 2019 Jan 10

IF 2,05

21. Stefania Basili, Roberto Carnevale, Cristina Nocella, Simona Bartimoccia, Valeria Raparelli, Giovanni Talerico, Lucia Stefanini, Giulio F. Romiti, Francesco Perticone, Gino R. Corazza, Fabio Piscaglia, Antonello Pietrangelo, Francesco Violi, and PRO-LIVER Collaborators Ainora Maria Elena, Andreozzi Paola, Andriulli Angelo, Angelico Francesco, Angelico Mario, Figliomeni Antonio, Anzaldi, Massimiliano, Arena Umberto, Averna Maurizio, Barone Milena, Bazzini Cristina, Bergamaschi, Gaetano, Bertoni Michele, Bianchi Giovanni Battista, Bianchi Paola Ilaria, Boari Benedetta, Bombonato Giancarlo, Bracco Christian, Brocco Silvia, Buonauro Agostino, Buttà Carmelo, Buzzetti Elena, **Cacciola Irene**, Calabria Stefano, Cangemi Roberto, Capeci William, Caradio Federica, Carderi Isabella, Carleo Pietro, Caroleo Benedetto, Carrabba Maria Domenica et al. Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis. *Hepatology Communications* 2019;3:504-512

IF 5,1

22. Francesco Violi, Gino Roberto Corazza, Stephen H. Caldwell, Giovanni Talerico, Giulio Francesco Romiti, Laura Napoleone, Francesco Perticone, Luigi Bolondi, Antonello Pietrangelo, Anna Rita Vestri, Valeria Raparelli, Stefania Basili, on behalf of PRO-LIVER Collaborative Group Ainora Maria Elena, Andreozzi Paola, Andriulli Angelo, Angelico Francesco, Angelico Mario, Figliomeni Antonio, Anzaldi, Massimiliano, Arena Umberto, Averna Maurizio, Barone Milena, Bazzini Cristina, Bergamaschi, Gaetano, Bertoni Michele, Bianchi Giovanni Battista, Bianchi Paola Ilaria, Boari Benedetta, Bombonato Giancarlo, Bracco Christian, Brocco Silvia, Buonauro Agostino, Buttà Carmelo, Buzzetti Elena, **Cacciola Irene**, Calabria Stefano, Cangemi Roberto, Capeci William, Caradio Federica, Carderi Isabella, Carleo Pietro, Caroleo Benedetto, Carrabba Maria Domenica et al. Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients. *Thromb Haemost.* 2019 Mar;119(3):496-499

IF 5,3

23. Maimone S, Saffioti F, Oliva G, Di Benedetto A, Alibrandi A, Filomia R, Caccamo G, Saitta C, **Cacciola I**, Pitrone C, Squadrito G, Raimondo G. Erectile dysfunction in compensated liver cirrhosis. *Dig Liver Dis.* 2019 Jun;51(6):843-849.

IF 5,2

24. D'Aliberti D, **Cacciola I**, Musolino C, Raffa G, Filomia R, Alibrandi A, Benfatto S, Beninati C, Saitta C, Giosa D, Romeo O, Raimondo G, Pollicino T. NS3 Variability in Hepatitis C Virus Genotype 1A Isolates from Liver Tissue and Serum Samples of Treatment-Naïve Patients with Chronic Hepatitis C. *Intervirology*. 2018;61(1):1-8.

IF 1,8

25. Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi FG, Levantesi F, Airoldi A, Boccia S, Svegliati-Baroni G, Faggioli S, Romanelli RG, Cozzolongo R, Di Marco V, Sangiovanni V, Morisco F, Toniutto P, Tortora A, De Marco R, Angelico M, **Cacciola I**, Elia G, Federico A, Massironi S, Guarisco R, Galioto A, Ballardini G, Rendina M, Nardelli S, Piano S, Elia C, Prestianni L, Cappa FM, Cesarini L, Simone L, Pasquale C, Cavallin M, Andrealli A, Fidone F, Ruggeri M, Roncadori A, Baldassarre M, Tufoni M, Zaccherini G, Bernardi M; ANSWER Study Investigators. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. *Lancet*. 2018 Jun 16;391(10138):2417-2429

IF 79,3

26. Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A, Abbati G, Alberti A, Andreone P, Andreoni M, Angeli P, Angelico M, Angarano G, Angrisani D, Antinori A, Antonini C, Avancini I, Barone M, Bruno R, Benedetti A, Bernabucci V, Blanc P, Boarini C, Boffa N, Boglione L, Borghi V, Borgia G, Brancaccio G, Brunetto M, **Cacciola I**, Calabrese P, Calvaruso V, et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. *Infection*. 2018. Oct;46(5):607-615.

IF 3,6

27. Calvaruso V, Cabibbo G, **Cacciola I**, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Laroocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents. *Gastroenterology*. 2018. Aug;155(2):411-421.

IF 22,7

28. Maimone S, Saffioti F, Filomia R, Caccamo G, Saitta C, Pallio S, Consolo P, Sabatini S, Sitajolo K, Franzè MS, **Cacciola I**, Raimondo G, Squadrito G. Elective endoscopic variceal ligation is

not a risk factor for bacterial infection in patients with liver cirrhosis. *Dig Liver Dis.* 2017 Dec 20. pii: S1590-8658(17)31329-4.

IF 5,2

29. **Cacciola I**, Filomia R, Alibrandi A, Franzè MS, Caccamo G, Maimone S, Saitta C, Saffiotti F, Squadrito G, Raimondo G. Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis. *Liver Int.* 2018 vol 38 1220-1229.

8,75

30. S. Basili ,V. Raparelli, L. Napoleone, G. Talerico , G.R. Corazza , F. Perticone , D. Sacerdoti , A. Andriulli, A. Licata, A. Pietrangelo , A. Picardi , G. Raimondo, and F. Violi on behalf of PRO-LIVER Collaborators Palasciano Giuseppe, D'Alitto Felicia, Palmieri Vincenzo Ostilio, Santovito Daniela, Di Michele Dario, Croce Giuseppe, Brocco Silvia, Fasolato Silvano, Cecchetto Lara, Bombonato Giancarlo, Bertoni Michele, Restuccia Tea, Andreozzi Paola, Liguori Maria Livia, Caroleo Benedetto, Perticone Maria, Staltari Orietta, Manfredini Roberto, De Giorgi Alfredo, Averna Maurizio, Giammanco Antonina, Granito Alessandro, Pettinari Irene, Marinelli Sara, Bolondi Luigi, Falsetti Lorenzo, Salvi Aldo, Durante-Mangoni Emanuele, Cesaro Flavio, Farinaro Vincenza, Ragone Enrico, Morana Ignazio, Ippolito Antonio, Iacobellis Angelo, Niro Grazia, Merla Antonio, Maimone Sergio, **Cacciola Irene**, Varvara Doriana, Drenaggi Davide, Staffolani Silvia, Vespasiani-Gentilucci Umberto, Galati Giovanni, Gallo Paolo, Davì Giovanni, Schiavone Cosima, Santilli Francesca et al Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study, *Am J Gastroenterol* 2018; 113:368–375;

IF 10,9

31. Violi F, Talerico G, Basili S; PRO-LIVER collaborators Palasciano Giuseppe, D'Alitto Felicia, Palmieri Vincenzo Ostilio, Santovito Daniela, Di Michele Dario, Croce Giuseppe, Brocco Silvia, Fasolato Silvano, Cecchetto Lara, Bombonato Giancarlo, Bertoni Michele, Restuccia Tea, Andreozzi Paola, Liguori Maria Livia, Caroleo Benedetto, Perticone Maria, Staltari Orietta, Manfredini Roberto, De Giorgi Alfredo, Averna Maurizio, Giammanco Antonina, Granito Alessandro, Pettinari Irene, Marinelli Sara, Bolondi Luigi, Falsetti Lorenzo, Salvi Aldo, Durante-Mangoni Emanuele, Cesaro Flavio, Farinaro Vincenza, Ragone Enrico, Morana Ignazio, Ippolito Antonio, Iacobellis Angelo, Niro Grazia, Merla Antonio, Maimone Sergio, **Cacciola Irene**, Varvara Doriana, Drenaggi Davide, Staffolani Silvia, Vespasiani-Gentilucci Umberto, Galati Giovanni, Gallo Paolo, Davì Giovanni, Schiavone Cosima, Santilli Francesca et al A Closer Look at Platelet Count and Prediction of Bleeding in Cirrhotic Patients. *Am J*

Gastroenterol. 2018 Sep;113(9):1397-1398. doi: 10.1038/s41395-018-0191-8. Epub 2018 Jun 29. PMID: 29955119 No abstract available.

IF 10,9

32. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M.; Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A, Tabone M, Andreoni M, Teti E, Angelico M, Persico M, Masarone M, Chiodera A, Solinas A, Delle Monache M, Cecere R, Maria Schimizzi A, Piovesan S, Campagnolo D, Chiara Piras M, Zolfino T, Paolo Russo F, Morelli O, Sangiovanni V, Onofrio M, Iodice V, Izzi A, Pirisi M, Danieli E, Vinci, M, Rizzardini G, Faggioli S, Pasulo L, D'Arminio Monforte A, Zuin M, Giorgini A, Simeone F, Piali G, Lo Guercio C, Federico A, Brancaccio G, Marrone, A, Abbati G, Boarini C, Borghi V, Bernabucci V, Corti G, Monti M, Rizzetto M, Martini S, Andreone, P, Gianstefani A, Lenzi, M, Verucchi G, Toniutto P, Borgia G, Caporaso N, Morisco F, Nardone G, Angrisani D, Giacometti A, Benedetti A, Tarantino G, Marsetti F, Tavio M, Novara S, Santantonio T, Serviddio G, Brunetto M, Coco B, Angarano G, Milella M, Barone M, Di Leo A, Ettore Sansonno D, **Cacciola I**, Boffa N, Saracco G, Di Biagio A, Picciotto A, DeLuca A, Calvaruso V, et al. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study *Lancet Gastroenterol Hepatol.* 2017 Jun;2(6):427-434.

IF 18,5

33. Cabibbo G, Petta S, Calvaruso V, **Cacciola I**, Cannavò MR, Madonia S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. *Aliment Pharmacol Ther.* 2017 Oct;46(7):688-695.

IF 9,5

34. Borgia F, **Cacciola I**, Filomia R, Vaccaro M, Squadrito G, Cannavò SP. Mucocutaneous toxicity during simeprevir treatment for hepatitis C. A single institution, retrospective case series. *Br J Clin Pharmacol.* 2017 May;83(5):1152-1154.

IF 4,3

35. **Cacciola I**, Scoglio R, Alibrandi A, Squadrito G, Raimondo G; SIMG-Messina Hypertransaminasemia Study Group. Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care. *Intern Emerg Med.* 2017 Mar;12(2):181-1

IF 5,4

36. Filomia R, Maimone S, Caccamo G, Saitta C, Visconti L, Alibrandi A, Caloggero S, Bottari A, Franzè MS, Gambino CG, Lembo T, Oliva G, **Cacciola I**, Raimondo G, Squadrito G. Acute kidney injury in cirrhotic patients undergoing contrast-enhanced computed tomography. *Medicine (Baltimore)*. 2016.Sep;95(38):e4836.

IF 1,9

37. Salerno F, Borzio M, Pedicino C, Simonetti R, Rossini A, Boccia S, **Cacciola I**, Burroughs AK, Manini MA, La Mura V, Angeli P, Bernardi M, Dalla Gasperina D, Dionigi E, Dibenedetto C, Arghittu M; AISF Investigators. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. *Liver Int*. 2017 Jan;37(1):71-79.

IF 8,7

38. Mwalitsa JP, Maimone S, Filomia R, Alibrandi A, Saitta C, Caccamo G, **Cacciola I**, Spinella R, Oliva G, Lembo T, Vadalà D, Gambino G, Raimondo G, Squadrito G. Atrial fibrillation in patients with cirrhosis. *Liver Int*. 2016Mar;36(3):395-400.

IF 8,7

39. Cartabellotta F, Di Marco V, Craxì A, Almasio P, Cammà C, Calvaruso V, Petta S, Colletti P, Mazzola G, Montalto G, Licata A, Giannitrapani L, Prestileo T, Di Lorenzo F, Dalle Nogare R, Sanfilippo A, Ficalora A, Madonia S, Tinè, F, Malizia G, Vassallo R, Volpes R, **Cacciola I**, Caccamo G, Maimone S, Saitta C, Squadrito G, Raimondo G, Tripodi N, D'Andrea S, Bertino G, Ardiri AL, Proiti Ma, Frazzetto E, Rigano G, Montineri A, Larocca, LN, Iacobello C, Cacopardo B, Benanti F, Russello M, Benigno R, Mannino G, Davì A, Di Rosolini MA, Digiacomio A, Fuduli G, Scifo G, Di Stefano M; Portelli V; Savalli F, Geraci C, Scalici I, Gioia G, Magro A, Alaimo G, Salvo A, Averna A, Lomonaco F, Quattrocchi U, Guarneri L, Maffeo F, Falzone E, Pulvirenti F. The HCV Sicily Network: a web-based model for the management of HCV chronic liver diseases. *European Review for Medical and Pharmacological Sciences*. 2016; 20 (1 Suppl): 11-16.

IF 3,5

40. Francesco Violi, Roberto Gino Corazza, Stephen Hugh Caldwell, Francesco Perticone, Angelo Gatta, Mario Angelico, Alessio Farcomeni, Michela Masotti, Laura Napoleone, Annarita Vestri, Valeria Raparelli, Stefania Basili, PRO-LIVER Collaborators: AinoraMaria Elena, Andreozzi Paola, Andriulli Angelo, Angelico Francesco, Angelico Mario, Figliomeni Antonio, Anzaldi Massimiliano, Arena Umberto, Averna Maurizio, Barone Milena, Bazzini Cristina, Bergamaschi Gaetano, Bertoni Michele, Bianchi, Giovanni Battista, Bianchi Paola Ilaria, Boari Benedetta, Bombonato Giancarlo, Bracco Christian, Brocco Silvia, Buonauro, Agostino, Buttà Carmelo, Buzzetti Elena, **Cacciola Irene**, Calabria Stefano, Cangemi Roberto, Capeci William,

Caradio, Federica, Carderi Isabella, Carleo Pietro, Caroleo Benedetto, Carrabba Maria Domenica, Castorani Luigi, Cavallo Maurizio, Cecchetto Lara, Cesaro Flavio, Cicco Sebastiano, Cimini Claudia et al. Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry, *Intern Emerg Med* (2016) 11:1059–1066.

IF 3,4

41. Maimone S, Tripodi G, Musolino C, **Cacciola I**, Pollicino T, Raimondo G. Lack of the NS5B S282T mutation in HCV isolates from liver tissue of treatment-naïve patients with HCV genotype-1b infection. *Antivir Ther.* 2015;20(2):245-7.

IF 2,1

42. Pollicino T, **Cacciola I**, Saffioti F, Raimondo G. Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. *J Hepatol.* 2014 Aug;61(2):408-17. Review.

IF 25,1

43. Squadrito G, **Cacciola I**, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. *J Hepatol.* 2013 Oct;59(4):696-700. doi: 10.1016/j.jhep.2013.05.043

IF 25,1

44. Cascio A, Stassi G, **Cacciola I**, Saitta C, Squadrito G. Fever and rhomboid target lesion in decompensated cirrhosis. *Lancet Infect Dis.* 2012 Jul;12(7):576.

IF 25,1

45. **Cacciola I**, Messineo F, Cacopardo B, Di Marco V, Galli C, Squadrito G, Musolino C, Saitta C, Pollicino T, Raimondo G. Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy. *Dig Liver Dis.* 2011 Dec;43(12):996-1000.

IF 5,2

46. Mangano C, Squadrito G, **Cacciola I**, Carpentieri M, Foti G, Raimondo G. Effectiveness of add-on pegylated interferon alpha-2a therapy in lamivudine-treated patient with chronic hepatitis B. *Ann Hepatol.* 2011 Jan-Mar;10(1):84-7.

IF 2,4

47. Messina MF, Squadrito G, Valenzise M, Maimone S, Iannelli S, Arrigo T, **Cacciola I**, Civa R, D'agata V, Raimondo G, De Luca F. Fibroscan: a new noninvasive method for evaluation of liver dysfunction in Turner syndrome. *Eur J Clin Invest.* 2011 Feb;41(2):183-8.

IF 4,7

48. Pollicino T, Raffa G, Santantonio T, Gaeta GB, Iannello G, Alibrandi A, Squadrito G, **Cacciola I**, Calvi C, Colucci G, Levrero M, Raimondo G. Replicative and transcriptional activities of

- hepatitis B virus in patientscoinfected withhepatitis B and hepatitis delta viruses. *J Virol.* 2011 Jan;85(1):432-9. **IF 4,5**
49. Raimondo G, Pollicino T, **Cacciola I**, Squadrito G. Occult hepatitis B virus infection. *J Hepatol.* 2007 Jan;46(1):160-70. Review **IF 25,1**
50. Squadrito G, Pollicino T, **Cacciola I**, Caccamo G, Villari D, La Masa T, Restuccia T, Cucinotta E, Scisca C, Magazzu D, Raimondo G. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. *Cancer.* 2006 Mar 15;106(6):1326-30. **IF 6,9**
51. **Cacciola I**, Spatari G, Pollicino T, Costantino L, Zimbaro G, Brancatelli S, Fenga C, Caccamo G, Squadrito G, Raimondo G. Virological profiles in hepatitis B virus inactive carriers: monthly evaluation in 1-year follow-up study. *Liver Int.* 2005 Jun; 25(3):555-63. **IF 8,7**
52. Raimondo G, Costantino L, Caccamo G, Pollicino T, Squadrito G, **Cacciola I**, Brancatelli S. Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. *J Hepatol.* 2004 Mar; 40(3):515-9. **IF 25,1**
53. Pollicino T, Squadrito G, Cerenzia G, **Cacciola I**, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. *Gastroenterology.* 2004 Jan;126(1):102-10. **IF 22,7**
54. Ferraro D, Bonura C, Giglio M, Di Stefano R, Almasio PL, Di Marco V, Craxi A,**Cacciola I**, Squadrito G, Raimondo G. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C. *J Biol Regul Homeost Agents.* 2003 Apr-Jun;17(2):172-5. **IF 1,6**
55. Pollicino T, Raffa G, Squadrito G, Costantino L, **Cacciola I**, Brancatelli S,Alafaci C, Florio MG, Raimondo G. TT virus has a ubiquitous diffusion in humanbody tissues: analyses of paired serum and tissue samples. *J Viral Hepat.* 2003Mar;10(2):95-102. **IF 3,7**
56. Squadrito G, Orlando ME, Pollicino T, Raffa G, Restuccia T, **Cacciola I**, DiMarco V, Picciotto A, Colucci G, Craxi A, Raimondo G. Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. *Am J Gastroenterol.* 2002 Jun;97(6):1518-23.

IF 10,9

57. **Cacciola I**, Cerenza G, Pollicino T, Squadrito G, Castellaneta S, Zanetti AR, Mieli-Vergani G, Raimondo G. Genomich eterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol. 2002 Mar; 36(3):426-32. **IF 25,1**
58. **Cacciola I**, Pollicino T, Squadrito G, Cerenza G, Villari D, de Franchis R, Santantonio T, Brancatelli S, Colucci G, Raimondo G. Quantification of intra hepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology. 2000 Feb;31(2):507-12. **IF 17,4**
59. Squadrito G, Orlando ME, **Cacciola I**, Rumi MG, Artini M, Picciotto A, Loiacono O, Siciliano R, Levvero M, Raimondo G. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection. J Hepatol. 1999 Jun; 30(6):1023-7. **IF 25,1**
60. **Cacciola I**, Pollicino T, Squadrito G, Cerenza G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999 Jul 1;341(1):22-6. **IF 91,2**
61. Pollicino T, Zanetti AR, **Cacciola I**, Petit MA, Smedile A, Campo S, Saggiocca L, Pasquali M, Tanzi E, Longo G, Raimondo G. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology. 1997 Aug;26(2):495-9. **IF 17,4**

Messina 14/06/2023

